What is the current market size and future outlook for the liquid biopsy market?
The liquid biopsy market size has grown rapidly in recent years. It will grow from $1.25 billion in 2024 to $1.46 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to advances in cancer research, non-invasiveness, personalized medicine, regulatory approvals, early cancer detection.
The liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.76 billion in 2029 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to expanding applications, cancer monitoring, emerging technologies, companion diagnostics, biomarker discovery. Major trends in the forecast period include cancer detection and monitoring, therapeutic monitoring, minimal residual disease (mrd) monitoring, liquid biopsy in non-oncological applications.
Get Your Free Sample of The Global Liquid Biopsy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp
How has the liquid biopsy market evolved, and what factors have shaped its growth?
Government funds for refining cancer detection drive the growth of the liquid biopsy market. Government funds help researchers in drug discovery, diagnosis, and treatment of diseases such as Cancer. For instance, in 2022, National Institute of Health (NIH), a US-based medical research agency was granted a fund of $46.6 billion and $6.9 billion was awarded to National Cancer Institute (NCI), an American cancer research agency, for advancing cancer research. Therefore, government funds positively impact the growth of the liquid biopsy market.
What are the major segments of the liquid biopsy market?
The liquid biopsy market covered in this report is segmented –
1) By Product: Assays Kits, Instruments, Services
2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring Orthopedics
3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers
Subsegments:
1) By Assays Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays, Protein-based Assays
2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments, Mass Spectrometry Instruments
3) By Services: Testing Services, Data Analysis Services, Laboratory Services, Custom Assay Development Services
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report
Which companies dominate the liquid biopsy market?
Major companies operating in the liquid biopsy market include QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Biocept Inc., Janssen Diagnostics LLC, Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Guardant Health AMEA, Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.
What are the top industry trends projected to impact the liquid biopsy market?
Companies are rapidly adopting new market dynamics and focusing primarily on advanced product launches, to meet the ever-increasing need for liquid biopsy products and services, to increase their revenue, and also for gaining a competitive edge over their rivals. For instance, in June 2023, Laboratory Corporation of America Holdings, a US-based healthcare company, launched a liquid biopsy test called Labcorp Plasma Focus. This test has been developed to identify cancer-associated biomarkers in individuals with advanced or metastatic solid tumors. The examination examines the cell-free DNA (cfDNA) circulating in a patient’s blood sample to construct a genomic profile of their tumor. This enables oncologists to enhance the management of their patients’ healthcare by creating personalized, precisely targeted therapy strategies. Thus, companies are investing in the development of advanced products in the liquid biopsy market.
What are the major regional insights for the liquid biopsy market, and which region holds the top position?
North America was the largest region in the liquid biopsy market in 2023. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Liquid Biopsy Market Report 2025 Offer?
The liquid biopsy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A liquid biopsy is a quick and painless substitute for surgical biopsies that allows medical professionals to learn a lot about a tumor from a small blood sample. A liquid biopsy is a diagnostic test performed on blood to detect the presence of any cancerous cells in the blood. It is used to detect cancer at an early stage.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2815
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
